M67.2
Synovial hypertrophy, not elsewhere classified
Clinical Classification Guidelines
Excludes Type 1
- villonodular synovitis (pigmented) (M12.2-)
Medical Intelligence & Overview
Synovial hypertrophy refers to the abnormal thickening of the synovial membrane, a vital tissue lining the joints that helps produce lubricating synovial fluid. This condition is classified under ICD-10 code M67.2 and is characterized by ongoing inflammation and tissue proliferation within the joint. Although it can occur in various joints, it is most commonly associated with conditions like rheumatoid arthritis, but it may also be due to other joint diseases or repeated injury. Recognizing and understanding synovial hypertrophy is essential for appropriate management and treatment, which aims to restore joint function and reduce pain.
Causes & Symptoms
Clinical Causes: Chronic inflammatory arthritis, such as rheumatoid arthritis Repetitive joint trauma or injury Joint infections leading to inflammation Degenerative joint diseases, like osteoarthritis Other autoimmune conditions affecting joints Prolonged joint overuse or stress Post-surgical changes in the joint
Key Symptoms: Joint swelling and puffiness Limited range of motion in the affected joint Persistent joint pain or discomfort Warmth and tenderness around the joint A feeling of joint weakness or instability Possible joint stiffness, especially in the morning In some cases, visible joint deformity
Diagnostic & Treatment
Diagnosis Path: Diagnosis of synovial hypertrophy generally involves a combination of clinical evaluation and imaging studies. A healthcare provider will assess symptoms, perform physical examinations, and may order the following tests: - **Ultrasound**: To visualize soft tissue changes around the joint and assess the extent of synovial thickening. - **Magnetic Resonance Imaging (MRI)**: Provides detailed images of the joint structures, confirming hypertrophy and evaluating associated inflammation. - **Joint Aspiration and Fluid Analysis**: May be performed to rule out infection or crystal-induced arthritis. - **Laboratory Tests**: Blood tests such as rheumatoid factor (RF), anti-CCP antibodies, ESR, and CRP levels to identify underlying autoimmune or inflammatory causes.
Treatment Protocols: Treatment focuses on managing inflammation, relieving symptoms, and preventing joint damage. Approaches may include: - **Medications**: Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs) for autoimmune causes. - **Physical Therapy**: Exercises to improve joint mobility and strengthen surrounding muscles. - **Rest and Joint Protection**: Techniques to avoid further injury or strain. - **Injections**: Corticosteroid injections directly into the joint to reduce inflammation. - **Surgical Intervention**: In severe cases where conservative treatments fail, procedures such as synovectomy (removal of hypertrophic synovial tissue) may be considered. - **Lifestyle Modifications**: Weight management and ergonomic adjustments to reduce joint stress.
Clinical Advice & FAQs
Billing Guidance
Is M67.2 a billable ICD-10 code?
Yes, M67.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M67.2?
Clinical documentation must specify the nature of Synovial hypertrophy, not elsewhere classified and any associated comorbidities for accurate reporting.
Cite this Clinical Reference